Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Methods br Transparency document br Introduction
2025-02-20

Methods Transparency document Introduction Epinephrine (EP) is a critical hormone and catecholamine neurotransmitter in nervous system of mammals.1, 2, 3 It has been known to accelerate and regulate heartbeat, blood pressure, bronchodilation, mydriasis, blood sugar and lipolysis, and can he
-
Indanone and its analogues are useful intermediates for the
2025-02-20

1-Indanone and its analogues are useful intermediates for the synthesis of compounds some of which have applications as pharmaceuticals, especially as analgesic and antihypertensive as well as tobacco flavoring agents. Indanones are commonly used as starting agent for the synthesis of ninhydrin whic
-
Based on the observation that
2025-02-20

Based on the observation that antipsychotic drugs increase 5-HT1A–D2 heteromerization level (Łukasiewicz et al., 2016), we set out to compare the effect of paroxetine to that of risperidone. Paroxetine, a potent SSRI, is very effective in the treatment of depression and anxiety disorders, e.g., gene
-
These results from the present study are
2025-02-20

These results from the present study are summarized in Table 1. Eight drugs (doxorubicin, epirubicin, daunorubicin, idarubicin, irinotecan, imatinib, sunitinib and gefitinib) inhibited 5-HT-induced 5-HT3A and 5-HT3AB currents; three (irinotecan, topotecan and mitoxantrone) showed different responses
-
A rational approach for the design of new steroid compounds
2025-02-20

A rational approach for the design of new steroid compounds as possible competitive inhibitors of CYP17 include chemical modification at C17 of the enzyme's natural substrates, pregnenolone (1) and progesterone (2), introducing groups with moderate to strong dipole properties at C20, such as oxime a
-
Consistent with the observation that mutations in the redox
2025-02-20

Consistent with the observation that mutations in the redox-partner binding site of P450c17 that reverse charge from basic to acidic (R347H, R358Q) cause 17,20-lyase deficiency (Geller et al, 1997, Geller et al, 1999), at least one POR mutation that changes a residue in the FMN domain from neutral t
-
Ryoichi et al modified potent clinical candidate VX with
2025-02-20

Ryoichi et al. modified potent clinical candidate VX-680 (6) with 3-cyano-6-(5-methyl-3-pyrazolamino)pyridine as Aurora kinase inhibitor. Substituted cyano pyridine derivative (7) inhibited proliferation of HCT-116 cells with an IC50 value of 115 nM. It showed tumor inhibition in mice model at a dos
-
While high fat diet models of insulin resistance are accepta
2025-02-20

While high-fat diet models of insulin resistance are acceptable approaches for the study of pre-diabetes in humans, they are not suitable for modeling progression towards established type2 diabetes. The pattern of activation of the lipoxygenase pathway in pre-clinical models of type2 diabetes has no
-
PGC mediated mitochondrial biogenesis in
2025-02-19

PGC-1α-mediated mitochondrial biogenesis in brown fat and endothelial dutp is in part regulated by eNOS and NO [28], [29]. Recent studies indicate that H2S not only augments NO bioavailability and signaling [11], [17], but provides protection against cardiac injury in an eNOS-dependent manner [15],
-
Recently rather than predicting categorical variables as in
2025-02-19

Recently, rather than predicting categorical variables as in classification, several studies begin to estimate continuous clinical variables from EP4 signaling inhibitor images. Therefore, instead of classify a subject into binary or multiple pre-determined categories or stages of the disease, regre
-
We start with a basic description of
2025-02-19

We start with a basic description of the MT-SGL model. Consider a multi-task learning (MTL) setting with k tasks. Let p be the number of covariates, shared across all the tasks, and n be the number of samples. Let denote the matrix of covariates, be the matrix of responses with each row correspondin
-
AR is an enzyme involved in conversion
2025-02-19

AR is an enzyme involved in conversion of glucose into sorbitol using NADPH as a cofactor [46]. This AR polyol pathway generates sorbitol accumulation and NADPH depletion. NADPH participates in detoxification via glutathione (GSH) reductase pathway [47]. Therefore, reduction of NADPH attenuates remo
-
br Conflict of interest statement br Introduction Human
2025-02-19

Conflict of interest statement Introduction Human saliva contains many detoxifying and antioxidant L002 like glutathione S-transferase, catalase, peroxidase, aldehyde dehydrogenase (ALDH), etc. [1]. Human salivary ALDH (hsALDH) protects individuals from toxic aldehydes contained in food as nat
-
br Downstream signalling of AKT A consensus phosphorylation
2025-02-19

Downstream signalling of AKT A consensus phosphorylation motif has been described for AKT substrates: R-X-R-X-X-S/T-B where X represents any amino apexbio dilution and B represents bulky hydrophobic residues (Alessi, Caudwell, Andjelkovic, Hemmings, & Cohen, 1996). Numerous AKT substrates have b
-
br Acknowledgements Dr Paul J
2025-02-19

Acknowledgements Dr. Paul J. Gasser is supported by the National Institutes of Health (grant number R01DA032895), and the Charles E. Kubly Mental Health Research Center. Dr. Christopher A. Lowry is supported by the National Institutes of Health (grant number R21 MH116263), the Department of the N
16022 records 23/1069 page Previous Next First page 上5页 2122232425 下5页 Last page